Role of endoscopic ultrasonography or magnetic resonance imaging for screening of pancreatic cancer in low-risk individuals

Table 2 Abnormal pancreatic lesions detected by magnetic resonance imaging and endoscopic ultrasound during surveillance, n (%)

	MRI (n = 1553)	EUS (n = 1811)	P value
Pancreatic lesion	40 (2.6)	231 (12.8)	< 0.001
Cystic lesion	35 (2.3)	182 (10.1)	< 0.001
Solid lesion	5 (0.3)	42 (2.3)	< 0.001
Cystic and solid lesion	0 (0)	7 (0.4)	0.014
Abdominal ultrasound finding	7 (0.5)	15 (0.8)	0.176
Cystic lesion	6 (0.4)	15 (0.8)	0.105
Solid lesion	1 (0.06)	0 (0)	0.280
Proven neoplasm
Adenocarcinoma	1 (0.06)	2 (0.11)	0.656
Neuroendocrine tumor	1 (0.06)	2 (0.11)	0.656
IPMN	4 (0.26)	0 (0)	0.031
Suspicious neoplasm
Branch-duct IPMN	7 (0.5)	42 (2.3)	< 0.001
Main-duct IPMN	1 (0.06)	1 (0.06)	0.913
Mixed-type IPMN	0 (0)	2 (0.11)	0.190
Serous cystic neoplasm	1 (0.06)	2 (0.11)	0.656
Mucinous cystic neoplasm	0 (0)	1 (0.06)	0.354
Solid pseudopapillary neoplasm	0 (0)	1 (0.06)	0.354

MRI: Magnetic resonance imaging; EUS: Endoscopic ultrasonography; IPMN: Intraductal papillary mucinous neoplasm.